Erasca Announces Updated Preliminary Phase 1 Data and Registration-Enabling Plans for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors

In a U.S. pancreatic cancer trial, RDE of 32 mg QD showed encouraging monotherapy activity, with a 57% uORR in 2L+ KRAS G12X patients and a median relative dose intensity of 100%. The results suggest tolerability/maintained dosing at full intensity while generating meaningful response rates, supporting a positive near-term clinical trajectory.

Analysis

In a U.S. pancreatic cancer trial, RDE of 32 mg QD showed encouraging monotherapy activity, with a 57% uORR in 2L+ KRAS G12X patients and a median relative dose intensity of 100%. The results suggest tolerability/maintained dosing at full intensity while generating meaningful response rates, supporting a positive near-term clinical trajectory.